Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China.
Department of Andrology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China.
Mol Med Rep. 2019 Oct;20(4):3782-3792. doi: 10.3892/mmr.2019.10636. Epub 2019 Sep 2.
Renal cell carcinoma (RCC) is the most common kidney malignancy, responsible for ~80% of all cases in adults. The pathogenesis of RCC is complex, involving alterations at both the genetic and epigenetic levels. Numerous signaling pathways, such as PI3K/Akt/mTOR and Wnt‑β‑catenin have been demonstrated to be associated with the tumorigenesis and development of RCC. Long non‑coding RNAs (lncRNAs) are functional RNA molecules involved in the initiation and progression of cancer, and investigating the effects of lncRNA could facilitate the development of novel treatments. The lncRNA regulator of reprogramming (ROR) is aberrantly expressed in a variety of tumors. However, its underlying mechanisms remain largely unknown. In the present study, ROR was found to be upregulated and microRNA (miR)‑206 was found to be downregulated in RCC tissues and cells. Furthermore, the knockdown of ROR inhibited the proliferation, migration and invasion of RCC cells. It was found that ROR binds to miR‑206, and that ROR‑induced cell proliferation and metastasis were reversed by the overexpression of miR‑206. In addition, the levels of miR‑206 and ROR were negatively correlated in RCC tissues. Furthermore, the overexpression of miR‑206 notably suppressed the proliferation, migration and invasion of RCC cells, and these effects were enhanced by the knockdown of vascular endothelial growth factor (VEGF); cell growth and metastasis induced by miR‑206 inhibitors could be reversed by the knockdown of VEGF. In addition, the expression levels of miR‑206 and VEGF were inversely correlated in RCC samples. In summary, the results of the present study revealed that ROR was upregulated in RCC tissues, which promoted tumor progression by regulating the miR‑206/VEGF axis. The present findings provided a novel insight into the potential functions of ROR in RCC, and the ROR/miR‑206/VEGF pathway may be a promising therapeutic target for the treatment of patients with RCC.
肾细胞癌 (RCC) 是最常见的肾脏恶性肿瘤,占成人所有病例的~80%。RCC 的发病机制复杂,涉及遗传和表观遗传水平的改变。许多信号通路,如 PI3K/Akt/mTOR 和 Wnt-β-连环蛋白,已被证明与 RCC 的肿瘤发生和发展有关。长链非编码 RNA (lncRNA) 是参与癌症发生和发展的功能性 RNA 分子,研究 lncRNA 的作用可以促进新的治疗方法的开发。调节重编程的 lncRNA (ROR) 在多种肿瘤中表达异常。然而,其潜在机制在很大程度上尚不清楚。在本研究中,发现 RCC 组织和细胞中 ROR 表达上调,miR-206 表达下调。此外,ROR 的敲低抑制了 RCC 细胞的增殖、迁移和侵袭。研究发现,ROR 与 miR-206 结合,miR-206 的过表达逆转了 ROR 诱导的细胞增殖和转移。此外,RCC 组织中 miR-206 和 ROR 的水平呈负相关。此外,miR-206 的过表达显著抑制了 RCC 细胞的增殖、迁移和侵袭,而 VEGF 的敲低增强了这些作用;miR-206 抑制剂诱导的细胞生长和转移可通过 VEGF 的敲低逆转。此外,RCC 样本中 miR-206 和 VEGF 的表达水平呈负相关。综上所述,本研究结果表明,ROR 在 RCC 组织中上调,通过调节 miR-206/VEGF 轴促进肿瘤进展。本研究结果为 ROR 在 RCC 中的潜在功能提供了新的见解,ROR/miR-206/VEGF 途径可能成为治疗 RCC 患者的有前途的治疗靶点。